UG2 Stock Overview A medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
AngioDynamics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for AngioDynamics Historical stock prices Current Share Price US$8.35 52 Week High US$8.95 52 Week Low US$4.76 Beta 0.67 1 Month Change 33.60% 3 Month Change 29.46% 1 Year Change 16.78% 3 Year Change -66.06% 5 Year Change -40.78% Change since IPO -23.02%
Recent News & Updates
AngioDynamics, Inc. to Report Q2, 2025 Results on Jan 08, 2025 Dec 20
AngioDynamics Receives FDA Clearance for the NanoKnife® System for Prostate Tissue Ablation Dec 10
AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry Study Oct 25
CEO, President & Director recently bought €110k worth of stock Oct 10
No longer forecast to breakeven Oct 06
First quarter 2025 earnings released: US$0.32 loss per share (vs US$1.15 profit in 1Q 2024) Oct 04 See more updates
AngioDynamics, Inc. to Report Q2, 2025 Results on Jan 08, 2025 Dec 20
AngioDynamics Receives FDA Clearance for the NanoKnife® System for Prostate Tissue Ablation Dec 10
AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry Study Oct 25
CEO, President & Director recently bought €110k worth of stock Oct 10
No longer forecast to breakeven Oct 06
First quarter 2025 earnings released: US$0.32 loss per share (vs US$1.15 profit in 1Q 2024) Oct 04
AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025 Oct 03
New minor risk - Shareholder dilution Sep 29
AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024 Sep 27
AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024 Sep 19
Full year 2024 earnings released: US$4.59 loss per share (vs US$1.33 loss in FY 2023) Jul 17
Forecast to breakeven in 2027 Jul 17 AngioDynamics, Inc. (NasdaqGS:ANGO) announces an Equity Buyback for $15 million worth of its shares.
AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024 Jul 09
New minor risk - Share price stability Jun 10
New minor risk - Shareholder dilution Apr 10
CEO, President & Director recently bought €62k worth of stock Apr 09
Third quarter 2024 earnings released: US$4.73 loss per share (vs US$0.24 loss in 3Q 2023) Apr 05
Insufficient new directors Apr 05
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024 Apr 05 AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024
Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc Apr 02
AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024 Mar 20
Angiodynamics, Inc. Announces Board Changes Feb 16 Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease AngioDynamics, Inc. Announces Manufacturing Operations Restructuring
AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024 Dec 08
AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism Dec 07
New minor risk - Share price stability Oct 18
Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024 Oct 06
First quarter 2024 earnings released: EPS: US$1.15 (vs US$0.33 loss in 1Q 2023) Oct 05
AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023 Sep 29
AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023 Sep 13
AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation Aug 17
Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study Aug 04
AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors Jul 25
AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024 Jul 13
Full year 2023 earnings released: US$1.33 loss per share (vs US$0.68 loss in FY 2022) Jul 13
AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023 Jun 21
New minor risk - Profitability Jun 13
Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million. Jun 09
Forecast to breakeven in 2026 May 31
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022) Mar 31
Key Executive recently sold €55k worth of stock Feb 03
AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023 Jan 06
Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.21 loss in 2Q 2022) Jan 06 Jan 06
AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023 Dec 16
Insufficient new directors Nov 16
AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism Nov 01
CEO, President & Director recently bought €155k worth of stock Oct 12
First quarter 2023 earnings released: US$0.33 loss per share (vs US$0.18 loss in 1Q 2022) Oct 07
AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023 Oct 07
AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022 Sep 23
AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022 Sep 09
Key Executive recently sold €110k worth of stock Aug 03
Full year 2022 earnings released: US$0.68 loss per share (vs US$0.82 loss in FY 2021) Jul 13
Forecast to breakeven in 2025 Jul 13
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2023 Jul 13
AngioDynamics, Inc. to Report Q4, 2022 Results on Jul 12, 2022 Jun 16
Key Executive recently sold €75k worth of stock May 03
Insufficient new directors Apr 27
Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2021) Apr 08
AngioDynamics, Inc. Provides Earnings Guidance for the Year 2022 Apr 08
CEO, President & Director recently bought €201k worth of stock Jan 19
AngioDynamics, Inc. Reports Impairment for the Three Months Ended November 30, 2021 Jan 07
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Jan 07
AngioDynamics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 Jan 07
Key Executive recently sold €84k worth of stock Oct 23
First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021) Oct 03
Full year 2021 earnings released: US$0.82 loss per share (vs US$4.39 loss in FY 2020) Jul 16
Angiodynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Jul 15
AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System Jun 09
Key Executive recently sold €70k worth of stock Apr 17
Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.15 loss in 3Q 2020) Mar 31
AngioDynamics, Inc. Revises Earnings Guidance for the Fiscal Year 2021 Mar 31
AngioDynamics, Inc. to Report Q3, 2021 Results on Mar 30, 2021 Mar 10
New 90-day high: €17.70 Mar 04
New 90-day high: €15.80 Feb 03
AngioDynamics, Inc. Announces Management Changes Feb 02
Independent Director recently sold €100k worth of stock Jan 23
Revenue beats expectations Jan 12
Second quarter 2021 earnings released: US$0.11 loss per share Jan 08
Revenue beats expectations Jan 08
New 90-day high: €12.60 Jan 06
AngioDynamics, Inc. to Report Q2, 2021 Results on Jan 07, 2021 Dec 12
New 90-day high: €12.50 Dec 05 Shareholder Returns UG2 DE Medical Equipment DE Market 7D -2.3% -2.9% -2.6% 1Y 16.8% -8.5% 6.9%
See full shareholder returns
Return vs Market: UG2 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is UG2's price volatile compared to industry and market? UG2 volatility UG2 Average Weekly Movement 11.7% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: UG2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UG2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure.
Show more AngioDynamics, Inc. Fundamentals Summary How do AngioDynamics's earnings and revenue compare to its market cap? UG2 fundamental statistics Market cap €346.21m Earnings (TTM ) -€232.92m Revenue (TTM ) €280.55m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) UG2 income statement (TTM ) Revenue US$292.73m Cost of Revenue US$141.36m Gross Profit US$151.36m Other Expenses US$394.39m Earnings -US$243.03m
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 08, 2025
Earnings per share (EPS) -5.98 Gross Margin 51.71% Net Profit Margin -83.02% Debt/Equity Ratio 0%
How did UG2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 08:30 End of Day Share Price 2024/12/20 00:00 Earnings 2024/08/31 Annual Earnings 2024/05/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources AngioDynamics, Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Taylor Barclays John Young Canaccord Genuity William Plovanic Canaccord Genuity
Show 14 more analysts 
